Search

everythinglearnresearchcommunity

for

Search:↓

Runx1 affects hair growth, cancer development, and autoimmune diseases in epithelial tissues.

TNFα, IFNγ, and Substance P significantly affect prolactin levels in human skin, suggesting new treatments for skin and hair conditions.

Cannabis, cryotherapy, and scalp cooling can help improve the quality of life for chemotherapy patients.

Exosomes show promise for improving wound healing, reducing aging signs, preventing hair loss, and lightening skin but require more research and better production methods.

New treatments for hair loss from alopecia areata may include targeting immune cells, using stem cells, balancing gut bacteria, applying fatty acids, and using JAK inhibitors.

CBD may improve skin and hair health, but its effective use and safety need more research.

More research is needed to confirm if laser therapy effectively treats hair loss.

Minoxidil is the only FDA-approved treatment for female hair loss, with other potential treatments needing more research for effectiveness.

Telogen effluvium is a reversible hair loss condition that requires a detailed diagnosis and often resolves on its own.

Hair loss causes stress and affects mental health; treatment and support needed.

Hair stops producing melanin as it transitions from the growth phase to the resting phase.

Estrogen affects hair growth and skin cell multiplication.

Telogen effluvium is a common type of hair loss that can resolve on its own or become chronic, with treatment depending on early diagnosis.

The telogen phase of hair growth is active and important for preparing hair follicles for regeneration, not just a resting stage.

Tiny particles from stem cells help activate hair growth cells and encourage hair growth in mice without being toxic.

How bad a woman's hair loss is doesn't always match how it affects her happiness and daily life.

Hair shedding is an active process that could be targeted to treat hair loss.

Chronic Telogen Effluvium is a hair loss condition in middle-aged women that usually doesn't lead to complete baldness.

Hair loss from Telogen Effluvium usually gets better within 6 months after addressing the cause.

The document says there are five types of hair loss conditions and different causes, including drugs.

Chronic Telogen Effluvium may resolve after years and is diagnosed by examining the patient's history and clinical signs, with treatment aimed at underlying causes and possibly minoxidil.

Shorter, thinner hairs indicate AGA, while longer, thicker hairs suggest CTE; counting and measuring shed hairs helps diagnose hair loss type.

COVID-19 may cause a temporary hair loss condition called telogen effluvium in some patients after recovery.

The document concludes that Telogen Effluvium is a hair loss disorder that can be assessed with the modified wash test and may be treated with clobetasol foam, with patient management being important.

COVID-19 infection may cause significant hair loss, but full hair recovery is likely without special treatment.

Wnt signaling is important for the change from the resting phase to the growth phase in human hair cycles.

The dietary supplement helped increase hair growth in women with hair loss.

Topical vitamin D3 does not prevent hair loss from chemotherapy.

Trichodynia found in 29% of TE or AGA patients, linked to psychological conditions.

Half of the patients treated with a specific drug for skin cancer experienced hair loss not related to the drug's dosage.